# A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures

> **NCT04244175** · PHASE2 · COMPLETED · sponsor: **AbbVie** · enrollment: 154 (actual)

## Conditions studied

- Seizures

## Interventions

- **DRUG:** Placebo
- **DRUG:** CVL-865

## Key facts

- **NCT ID:** NCT04244175
- **Lead sponsor:** AbbVie
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-01-27
- **Primary completion:** 2024-05-21
- **Final completion:** 2024-05-21
- **Target enrollment:** 154 (ACTUAL)
- **Last updated:** 2025-05-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04244175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04244175, "A Trial of the Efficacy and Safety of CVL-865 as Adjunctive Therapy in the Treatment of Focal Onset Seizures". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT04244175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*